Skip to main content
SpringerLink
Log in

New Governance Models for Discoveries of Vaccine Science

  • Chapter
  • First Online:
Management of Knowledge-Intensive Organizations

  • 510 Accesses

Abstract

In assuming World Health Organization as a KIO, this chapter examines (i) mechanisms of capture in research partnerships and (ii) seeks directions to extend trusteeship governance. Bodies of investigation are translational research of vaccine science for multidrug resistant tuberculosis (MDR-TB). In spite of the scientific progress of the ability to sequence the entire genomes of bacteria, an approved tuberculosis vaccine is only one since the early twentieth century. A change of the whole system of vaccine science is likely to undermine KIOs’ unique responsibilities to control pathogen. Threats identified are dependence in the co-specialization alliance. By regarding vaccine discoveries as a common good, this chapter extends the trusteeship governance to encompass common good-based stakeholder theory that positively positions the private incentives while retaining unique responsibilities of KIOs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Anderson, P., & Woodworth, J. S. (2014). Tuberculosis vaccines—Rethinking the current paradigm. Trends in Immunology, 35(8), 387–395.

    Article  Google Scholar 

  • Argandona, A. (1998). Stakeholder theory and the common good. Journal of Business Ethics, 17, 1093–1102.

    Article  Google Scholar 

  • Austin J. E. (2000). The collaboration challenge: How nonprofits and businesses succeed through strategic alliances. San Francisco: Jossey-Bass.

    Google Scholar 

  • Barben, D., Fischer, E., Selin, C., & Guston, D. H. (2008). Anticipatory governance of nanotechnology: Foresight, engagement, and integration. In E. J. Hackett, O. Amsterdamska, M. Lynch, & J. Wajcman (Eds.), The handbook of science and technology studies (pp. 979–1000). Cambridge: The MIT Press.

    Google Scholar 

  • Barrett, D., Austin, J., & McCarthy, S. (2002). Cross-sector collaboration: Lessons from the international trachoma initiative. In M. R. Reich (Ed.), Public-private partnerships for public health (pp. 41–65). Cambridge, MA: Harvard Centre for Population and Development Studies.

    Google Scholar 

  • Bartlett, C., & Ghoshal, S. (1989). Managing across borders: The transnational solution. Cambridge: Harvard Business School Press.

    Google Scholar 

  • Besley, T., & Ghatak, M. (2001). Government versus private ownership of public goods. The Quarterly Journal of Economics, 116(4), 1343–1372.

    Google Scholar 

  • Burget, M., Bardone, E., & Pedaste, M. (2016). Definitions and conceptual dimensions of responsible research and innovation: A literature review. Science and Engineering Ethics, 1–19. https://doi.org/10.1007/s11948-016-9782-1.

  • Buse, K., & Harmer, A. (2007). Seven habits of highly effective global public-private health partnerships: Practice and potential. Social Science and Medicine, 64, 259–271.

    Article  Google Scholar 

  • Buse, K., & Walt, G. (2000). Global public-private partnerships: Part 1—A new development in health? Bulletin of the World Health Organization, 78(4), 549–561.

    Google Scholar 

  • Buse, K., & Walt, G. (2002). The World Health Organization and global public-private health partnerships: In search of ‘good’ global health governance. In M. R. Reich (Ed.), Public-private partnerships for public health (pp. 169–195). Cambridge, MA: Harvard Centre for Population and Development Studies.

    Google Scholar 

  • Caves, R. E. (2007). Multinational enterprise and economic analysis (3rd ed.). New York: Cambridge University Press.

    Google Scholar 

  • Cayabyab, M. J., Macovei, L., & Campos-Nelo, A. (2012). Current and novel approaches to vaccine development against tuberculosis. Frontiers in Cellular and Infection Microbiology, 2, 154.

    Article  Google Scholar 

  • Chen, L. C., Evans, T. G., & Cash, R. A. (1999). Health as a global public good. In I. Kaul, I. Grunberg, & M. Stern (Eds.), Global public goods (pp. 284–304). New York: Oxford University Press.

    Google Scholar 

  • Choi, C., & Millar, C. (2005). Knowledge entanglement. Hampshire and New York: Palgrave Macmillan.

    Book  Google Scholar 

  • Chorev, N. (2012). The World Health Organization between North and South. Ithaca: Cornel University Press.

    Book  Google Scholar 

  • Christensen, T. (2011). University governance reforms: Potential problems of more autonomy? The International Journal of Higher Education and Educating Planning, 62(4), 503–517.

    Google Scholar 

  • Cook-Deagan, R. (2007). The science commons in health research: Structure, function, and value. Journal of Technology Transfer, 32(3), 133–156.

    Article  Google Scholar 

  • Doz, Y., & Hamel, G. (1998). Alliance advantage: The art of creating value through partnering. Boston: Harvard Business School Press.

    Google Scholar 

  • Farmer, P., & Kim, J. Y. (1998). Community based approaches to the control of multidrug resistant tuberculosis: Introducing “DOTS-plus”. British Medical Journal, 317(5), 671–674.

    Article  Google Scholar 

  • Finnis, J. (1980). Natural law and natural rights. Oxford: Oxford University Press.

    Google Scholar 

  • Forsberg, E.-M., Gianluca, Q., O’Kane, H., Karapiperis, T., Van Woensel, L., & Arnaldi, S. (2015). Assessment of science and technologies: Advising for and with responsibility. Technology in Society, 42, 21–27.

    Google Scholar 

  • Frost, L., Reich, M. R., & Fujisaki, T. (2002). A partnership for ivermectin: Social worlds and boundary objects. In M. R. Reich (Ed.), Public-private partnerships for public health (pp. 87–113). Cambridge, MA: Harvard Centre for Population and Development Studies.

    Google Scholar 

  • Ghobadian, A., Gallear, D., Viney, H., & O’Regan, N. (2004). Future of the public-private partnership. In A. Ghobadian, D. Gallear, N. O’Regan, & H. Viney (Eds.), Public-private partnerships: Policy and experience (pp. 271–302). Hampshire and New York: Palgrave Macmillan.

    Google Scholar 

  • Gottweis, H., Salter, B., & Waldby, C. (2009). The global politics of human embryonic stem cell science: Regenerative medicine in transition. New Hampshire and New York: Palgrave Macmillan.

    Book  Google Scholar 

  • Greco, L. (2015). Imperfect bundling in public-private partnerships. Journal of Public Economic Theory, 17(1), 136–146.

    Google Scholar 

  • Haas, M. (2010). The double-edged sword of autonomy and external knowledge: Analyzing team effectiveness in a multinational organization. Academy of Management Journal, 53(5), 989–1008.

    Article  Google Scholar 

  • Hart, O. (2003). Incomplete contracts and public ownership: Remarks, and application to public-private partnerships. The Economic Journal, 13(March), C69–C76.

    Google Scholar 

  • Harvard Medical School (Rosenberg, J., & Rhatigan, J.). (2011). Multidrug-resistant tuberculosis treatment in Peru, Cases in Global Health Delivery, Harvard University.

    Google Scholar 

  • Hofmann, D. A., & Frese, M. (Eds.). (2011). Errors in organizations. New York: Routledge.

    Google Scholar 

  • Isaakidis, P., Cox, H., Varghese, B., Montaldo, C., Mansoor, H., Ladomirska, J., … Reid, T. (2011). Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLoS One, 6(12), e28066, 2–9.

    Google Scholar 

  • Kanter, R. M. (1997). From spare change to real change: The social sector as beta site for business innovation (pp. 153–177). Cambridge: Harvard Business School on Innovation, Harvard Business School Press.

    Google Scholar 

  • Kenworthy, N., MacKenzie, R., & Lee, K. (Eds.). (2016). Case studies on corporations & global health governance: Impacts, influence and accountability. London: Rowman & Littlefield International.

    Google Scholar 

  • Kivleniece, I., & Quelin, B. V. (2012). Creating and capturing value in public-private ties: A private actor’s perspective. Academy of Management Review, 37(2), 272–299.

    Article  Google Scholar 

  • Klein, P. G., Mahoney, J. T., McGahan, A. M., & Pitelis, C. N. (2010). Toward a theory of public entrepreneurship. European Management Review, 7, 1–15.

    Google Scholar 

  • Kogut, B., & Zander, U. (1992). Knowledge of the firm. Combinative Capabilities, and the Replication of Technology, Organization Science, 3(3), 383–397.

    Google Scholar 

  • Leonelli, S. (2010). The commodification of knowledge exchange: Governing the circulation of biological data. In H. Radder (Ed.), The commodification of academic research: Science and the modern university (pp. 132–157). Pittsburgh: Pittsburgh University Press.

    Google Scholar 

  • Lienhardt, C., Lonnroth, K., Menzies, D., Balasegaram, M., Chakaya, J., Cobelens, F., … Raviglione, M. (2016). Translational research for tuberculosis elimination: Priorities, challenges, and actions. PLoS Medicine, 13(3), e1001965. doi:10.1371.

    Google Scholar 

  • Lucas, A. O. (2002). Public-private Partnerships: Illustrative examples. In M. R. Reich (Ed.), Public-private partnerships for public health (pp. 19–39). Cambridge, MA: Harvard Centre for Population and Development Studies.

    Google Scholar 

  • Maclagan, P. (1998). Management and morality: A developmental perspective. Thousand Oaks: Sage.

    Google Scholar 

  • Mahoney, J. T., McGahan, A. M., & Pitelis, C. N. (2009). The interdependence of private and public interests. Organization Science, 20(6), 1034–1052.

    Article  Google Scholar 

  • Mahoney, R., Pablos-Mendez, A., & Ramachandran, S. (2004). The introduction of new vaccines into developing countries: III. The role of intellectual property. Vaccine, 22(5), 786–792. https://doi.org/10.1016/j.vaccine.2003.04.001.

    Article  Google Scholar 

  • Marchant, G. E., & Wallach, W. (2013). Governing the governance of emerging technologies. In G. E. Marchant, K. E. Abbott, & B. Allenby (Eds.), Innovative governance models for emerging technologies (pp. 136–152). Cheltenham: Edward Elgar.

    Google Scholar 

  • Merton, R. K. (1942). A note on science and democracy. Journal of Legal and Political Sociology, 1, 115–126.

    Google Scholar 

  • Migliori, G. B., Matteelli, A., Cirillo, D., & Pai, M. (2008). Diagnosis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Current standards and challenges. Canadian Journal of Infectious Diseases and Medical Microbiology, 19(2), 169–172.

    Article  Google Scholar 

  • Mowery, D. C. (2001). The US national innovation system after the Cold War. In P. Laredo, & P. Mustar (Eds.), Research and innovation policies in the new global economy: An international comparative analysis (pp. 15–46). Cheltenham and Northamption: Edward Elgar Publishing.

    Google Scholar 

  • North, D. (1990). Institutions, institutional change and economic performance. Cambridge: Cambridge University Press.

    Book  Google Scholar 

  • Okada, E. (2017, June). Responsible organization, partnership design, and governance in addressing global common goods. Presented at International Conference of Responsible Organization in Global Context, organized by Georgetown University and Universite de Versailles, Washington, DC.

    Google Scholar 

  • Okada, E. (2018). Knowledge corruption and governance in academic knowledge-intensive organizations: The case of molecular mutations research. Journal of Public Affairs, 18e1698. https://doi.org/10.1002/pa.1698.

  • Owen, R., Macnaghten, P., & Stilgoe, J. (2012). Responsible research and innovation: From science in society to science for society, with society. Science and Public Policy, 39, 751–760.

    Article  Google Scholar 

  • Palfrey, Q. A. (2017). Expanding access to medicine and promoting innovation: A practical approach. Georgetown Journal on Poverty Law and Policy, 24(2), 162–197.

    Google Scholar 

  • Pfeffer, J., & Salancik, G. R. (1978). The external control of organizations: A resource dependence perspective. New York: Harper & Row.

    Google Scholar 

  • Prabowo, S. A., Groschel, M. I., Schmidt, E. D. L., Skrahina, A., Mihaescu, T., Hastuk, S., … van der Werf, T. S. (2013). Targeting multidrug-resistant tuberculosis by therapeutic vaccines. Medical Microbiology and Immunology, 302, 95–104.

    Google Scholar 

  • Radder, H. (2010). The commodification of academic research. In H. Radder (Ed.), The commodification of academic research: Science and the modern university (pp. 1–23). Pittsburg: University of Pittsburg Press.

    Google Scholar 

  • Rangan, S., Samii, R., & van Wassenhove, L. K. (2006). Constructive partnerships: When alliances between private firms and public actors can enable creative strategies. Academy of Management Review, 31(3), 738–751.

    Article  Google Scholar 

  • Rappuoli, R., Blank, S., & Lambert, P. H. (2011). Vaccine discovery and translation of new vaccine technology. Lancet, 378, 360–368.

    Article  Google Scholar 

  • Reich, M. R. (Ed.). (2002a). Public-private partnerships for public health. Cambridge (US): Harvard Center for Population and Development Studies.

    Google Scholar 

  • Reich, M. R. (2002b). Introduction: Public-private partnerships for public health. In M. R. Reich (Ed.), Public-private partnerships for public health (pp. 1–18). Cambridge, USA: Harvard Center for Population and Development Studies.

    Google Scholar 

  • Reichman, L. B., & Tanne, J. H. (2002). Timebomb—The global epidemic of multidrug resistant tuberculosis. New York: McGraw Hill.

    Google Scholar 

  • Roberts, M. J., Breitenstein, A. G., & Roberts, C. S. (2002). The ethics of public-private partnerships. In M. R. Reich (Ed.), Public-private partnerships for public health (pp. 67–85). Cambridge: Harvard Centre for Population and Development Studies.

    Google Scholar 

  • Rosenberg, J., & Rhatigan, J. (2011). Multidrug-resistant tuberculosis treatment in Peru, Cases in Global Health Delivery, Harvard.

    Google Scholar 

  • Sachs, J. (2001). Thinking boldly. Bulletin of the World Health Organization, 79(8), 772.

    Google Scholar 

  • Schmitz, P. W. (2014). Optimal ownership of public goods reconsidered. Economics Letters, 125, 21–24.

    Article  Google Scholar 

  • Smith, R. (2009). Global health governance and global public goods. In K. Buse, W. Heine, & N. Drager (Eds.), Making sense of global health governance: A policy perspective (pp. 122–136). New York: Palgrave Macmillan.

    Google Scholar 

  • Stevenson, M. (2016). The entrenchment of the public-private partnership paradigm. In N. Kenworthy, R. MacKenzie, & K. Lee (Eds.), Case studies on corporations & global health governance: Impacts, influence and accountability (pp. 119–129). London: Rowman & Littlefield International.

    Google Scholar 

  • Stewart, R. J., Tsang, C. A., Pratt, R. H., Price, S. F., & Langer, A. J. (2018). Tuberculosis—United States, 2017, Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report 67, 317–323. http://dx.doi.org/10.15585/mmwr.mm6711a2.

  • Stilgoe, J., Owen, R., & Macnaghten, P. (2013). Developing a framework for responsible innovation. Research Policy, 42, 1568–1580.

    Article  Google Scholar 

  • Stiglitz, J. (1999). Knowledge as a public good, global public goods. In I. Kaul, I. Grunberg, & M. Stern (Eds.), Global public goods (pp. 308–325). New York: Oxford University Press.

    Chapter  Google Scholar 

  • Vakili, K., & McGahan, A. M. (2016). Health care’s grand challenges: Stimulating basic science on diseases that primarily afflict the poor. Academy of Management Journal, 59(6), 1917–1939.

    Article  Google Scholar 

  • Velasquez, M. (1983). Why corporations are not morally responsible for anything they do. Business and Professional Ethics Journal, 2(3), 1–18.

    Article  Google Scholar 

  • Von Nordenflycht, A. (2010). What is a professional service firm? Toward a theory and taxonomy of knowledge—Intensive firms. Academy of Management Review, 25(1), 155–174.

    Google Scholar 

  • Von Schomberg, R. (2013). A vision of responsible research and innovation. In R. Owen, J. Bessant, & M. Heintz (Eds.), Responsible innovation: Managing the responsible emergence of science and innovation in society. Chichester: Wiley-Blackwell.

    Google Scholar 

  • Wahl, H., & Kogut, B. (2007). Eli Lilly multi-drug resistant tuberculosis partnership. Fontainebleau: INSEAD Case.

    Google Scholar 

  • Walter, N. D., Strong, M., Belknap, R., Ordway, D. J., Daley, C. L., & Chan, E. D. (2012). Translating basic science insight into public health action for multidrug-and extensively drug-resistant tuberculosis. Respirology, 17, 772–791.

    Google Scholar 

  • Williamson, O. E. (1979). Transaction-cost economics: The governance of contractual relations. The Journal of Law and Economics, 22(2), 233–261.

    Article  Google Scholar 

  • Williamson, O. E. (1991). Comparative economic organization: The analysis of discrete structural alternatives. Administrative Science Quarterly, 36, 269–296.

    Article  Google Scholar 

  • Williams, O. D., & Rushton, S. (2011). Private actors in global health governance. In S. Rushton & O. Williams (Eds.), Partnerships and foundations in global health governance (pp. 1–28). New York: Palgrave Macmillan.

    Google Scholar 

  • World Bank. (1994). Governance: The World Bank’s experience. Washington, D.C.: World Bank.

    Google Scholar 

  • World Health Organization. (2008). Policy statement: Molecular line probe assay for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). http://www.who.int/tb/features_archive/policy_statement.pdf?ua=1.

  • World Health Organization. (2011). Priorities in operational research to improve tuberculosis care and control. Geneva: WHO Press.

    Google Scholar 

  • World Health Organization. (2013, 2017). Guidelines for the management of multidrug-resistant tuberculosis (MDR-TB) in Myanmar. Myanmar: WHO Country Office for Myanmar.

    Google Scholar 

  • World Health Organization. (2014). The end Tb strategy. Geneva: WHO.

    Google Scholar 

  • World Health Organization. (2015). A global action framework for TB research. Geneva: WHO Press.

    Google Scholar 

  • World Health Organization. (2016). Country cooperation strategy. Geneva: WHO Press.

    Google Scholar 

  • World Health Organization. (2018, May 24). The top 10 causes of death. News: Fact Sheets. Geneva: WHO. www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.

Download references

Author information

Authors and Affiliations

  1. Boston Cancer Policy Institute, Somerville, MA, USA

    Ellie Okada

Authors
  1. Ellie Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ellie Okada .

Rights and permissions

Reprints and permissions

Copyright information

© 2019 The Author(s)

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Okada, E. (2019). New Governance Models for Discoveries of Vaccine Science. In: Management of Knowledge-Intensive Organizations. Palgrave Macmillan, Cham. https://doi.org/10.1007/978-3-319-97373-9_6

Download citation

Publish with us

Policies and ethics

Search

Navigation